About the project
The incidence of stroke is predicted to increase with the aging population. A large fraction of these are caused by a clot in the brain and are called ischemic stroke (87%) and the rest (13%) are due to rupture of brain vessels and are called hemorrhagic stroke.
The current pharmacological treatment for ischemic stroke is tPA but this has many shortcomings:
- There is a short time window in which tPA can be applied (< 4.5 h) after which the clot properties change and tPA is not effective.
- tPA causes severe bleeding in the brain of 2-5% of the patients who receive this drug (hemorrhagic transformation).
- tPA is ineffective against clots in larger vessels, and these are treated with surgery to remove the clot.
- Only 3-10 % of patients receive tPA treatment, and only some actually benefit from it.
- Surgical removal of the clots is becoming an increasingly viable option, but this is only possible if the clots are in large vessels in some parts of the brain. This operation can only be performed in specialized centers.
Treatment of ischemic stroke is one of the most intensively researched topics with many promising developments in designing a new generation of thrombolytic, neuroprotective, and neuroregenerative factors as well as surgical techniques. Although thousands of drugs are effective in animal models, they show no efficacy in humans. Thus, there is a big translation gap.
We have discovered a factor (FSAP) that helps to dissolve clots faster and protects the brain in stroke.
Outcomes
This project addresses issues related to the treatment of stroke patients in the acute situation.
We have demonstrated that a circulating blood protease, Factor FVII Activating Protease (FSAP), speeds up lysis of blood clots by tPA in vitro and has neuroprotective effects on cultured brain cells. Recombinant FSAP improves the outcome of stroke in mouse models. Thus, FSAP represents a novel treatment, and our ambition is to develop this concept further.
Financing
NFR: 2016-2020
Cooperation
Stiftelsen Norsk Luftambulanse (SNLA)